Cantor Fitzgerald Research Analysts Lift Earnings Estimates for NewLink Genetics Co. (NLNK)

NewLink Genetics Co. (NASDAQ:NLNK) – Equities researchers at Cantor Fitzgerald lifted their FY2018 earnings per share estimates for shares of NewLink Genetics in a report issued on Tuesday, May 22nd. Cantor Fitzgerald analyst M. Goldstein now expects that the biotechnology company will earn ($1.98) per share for the year, up from their prior estimate of ($2.14). Cantor Fitzgerald has a “Hold” rating and a $7.00 price target on the stock. Cantor Fitzgerald also issued estimates for NewLink Genetics’ FY2019 earnings at ($1.42) EPS.

NLNK has been the topic of several other reports. Robert W. Baird cut NewLink Genetics from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $22.00 to $5.00 in a report on Monday, April 9th. Jefferies Group cut NewLink Genetics from a “buy” rating to a “hold” rating in a report on Friday, April 6th. Bank of America cut NewLink Genetics from a “buy” rating to a “neutral” rating in a report on Friday, April 6th. ValuEngine cut NewLink Genetics from a “sell” rating to a “strong sell” rating in a report on Tuesday, May 8th. Finally, Stifel Nicolaus restated a “buy” rating and set a $21.00 price target (down from $25.00) on shares of NewLink Genetics in a report on Friday, March 2nd. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $10.50.

NASDAQ:NLNK opened at $5.40 on Thursday. The stock has a market cap of $198.09 million, a PE ratio of -2.35 and a beta of 1.25. NewLink Genetics has a 1-year low of $3.75 and a 1-year high of $19.30.

NewLink Genetics (NASDAQ:NLNK) last released its earnings results on Thursday, May 3rd. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.06. NewLink Genetics had a negative return on equity of 55.64% and a negative net margin of 193.44%. The firm had revenue of $9.90 million for the quarter, compared to analysts’ expectations of $5.78 million.

Several large investors have recently added to or reduced their stakes in NLNK. Creative Planning bought a new stake in shares of NewLink Genetics during the fourth quarter worth about $152,000. Schwab Charles Investment Management Inc. boosted its holdings in NewLink Genetics by 22.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 100,944 shares of the biotechnology company’s stock valued at $819,000 after acquiring an additional 18,712 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in NewLink Genetics by 241.6% in the fourth quarter. Acadian Asset Management LLC now owns 19,470 shares of the biotechnology company’s stock valued at $158,000 after acquiring an additional 13,770 shares during the last quarter. Swiss National Bank boosted its holdings in NewLink Genetics by 26.6% in the fourth quarter. Swiss National Bank now owns 45,200 shares of the biotechnology company’s stock valued at $367,000 after acquiring an additional 9,500 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in NewLink Genetics by 7.9% in the fourth quarter. Wells Fargo & Company MN now owns 373,682 shares of the biotechnology company’s stock valued at $3,031,000 after acquiring an additional 27,242 shares during the last quarter. Institutional investors own 53.04% of the company’s stock.

NewLink Genetics Company Profile

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.

Earnings History and Estimates for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply